Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DOSE FINDING STUDY OF PF-05212384 WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH ADVANCED SOLID TUMOR

Trial Profile

DOSE FINDING STUDY OF PF-05212384 WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH ADVANCED SOLID TUMOR

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gedatolisib (Primary) ; Carboplatin; Paclitaxel
  • Indications Adenocarcinoma; Endometrial cancer; Lung cancer; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer
  • Focus Adverse reactions

Most Recent Events

  • 15 Jul 2021 Following the first 9 patients treated with the above mentioned schedule, the study was amended, dose of Gedatolisib 110mg and 130 mg has added in the treatment.
  • 15 Jul 2021 Results published in the Clinical Cancer Research
  • 21 Sep 2020 According to results presented at the 45th European Society for Medical Oncology Congress, Carboplatin was initially administered at AUC5 on day 8 and Paclitaxel at 80 mg/m2 on day 8, 15 and 22 and after a protocol amendment on day 1 and day 1, 8 and 15 respectively, in 28d cycles.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top